Business Wire

DXC Technology Named a Leader in Everest Group’s Life Insurance and Pensions Report

6.4.2022 15:30:00 EEST | Business Wire | Press release

Share

DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has been named a Leader by research firm Everest Group in its PEAK Matrix® for Life and Pensions Insurance Business Process Services/Third Party Administrators Service Provider 2022 report.

DXC provides a range of solutions to the insurance industry including business process services (BPS) and insurance software. It also serves as a licensed third-party administrator (TPA) in the U.S. and licensed broker-dealer in Canada, using its deep expertise in compliance and regulation.

The report acknowledged DXC’s position in the life insurance and pensions market with its highest designated category, noting the following:

  • DXC has reaffirmed its commitment to the life and pensions (L&P) space through its strategic BPS focus, leveraging its differentiated ownership of the technology stack and especially its policy administration platforms.
  • DXC has augmented its platform-led approach and is aggressively taking its DXC Assure for Life and Wealth platform to the market, especially for new (policy) blocks and new product launches, and is experiencing good deal momentum. Additionally, DXC Assure’s integration with both proprietary and partner/insurtech solutions further strengthens this value proposition.
  • DXC has firmed up its presence to service new/active blocks, while simultaneously focusing on large closed-block deals where it already holds significant experience and has invested in modernizing conversion methodologies.
  • DXC has expanded its North American footprint through strategic BPS wins in Canada.

“Recognizing DXC as a Leader and giving us high marks for our vision and strategy reinforces the strength of our insurance services and platform-led approach,” said Ray August, president, Insurance Software and Business Process Solutions. “We will continue to invest in our life and wealth solutions, helping our customers bridge from the old to the new to better serve their customers and grow market share.”

“DXC has continued to maintain a strong position in the L&P insurance BPS/third-party administrator (TPA) market, with its large and expanding clientele, commitment to developing IT/BPS synergies through its proprietary BPaaS capabilities, and end-to-end scope of services,” said Somya Bhadola, Practice Director, Everest Group. “A balanced and customized strategic approach across new, active and closed blocks demonstrates DXC’s commitment to this market and positions it as a Leader.”

This Everest Group report assessed 20 providers based on their vision, capabilities and market impact across North America, and categorized them as Leaders, Major Contenders or Aspirants. DXC was one of only five Leaders, a position the company has held for the past 7 years when the report launched.

A custom version of the Everest Group PEAK Matrix® for Life and Pensions (L&P) Insurance BPS/TPA Service Provider 2022 is available here. DXC was also recently recognized by Everest as a Leader in its Cloud Services PEAK Matrix Assessment 2022.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Frank Hurteau
Corporate Media Relations
+1 (703) 582 4665
> Email

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye